PhRMA Urges Court Again to Strike Down 340B Dispute Resolution Process

PhRMA's lawsuit challenging the 340B administrative dispute resolution process is being heard in federal district court in Baltimore.

Regulations establishing a binding administrative dispute resolution (ADR) process for the 340B program were rushed into place last December to defeat lawsuits, are fatally flawed legally and constitutionally, and should be struck down, the main U.S. trade association for drug

Read More »

Biden Wants to Rescind Trump’s Most Favored Nation Proposal That Received Widespread Criticism from Drug Industry and 340B Providers

The Biden administration plans to rescind ex-President Trump's Most Favored Nation interim final rule that would peg Medicare reimbursement for some drugs to the lowest price that drug manufacturers get in similar countries.

The Biden administration plans to rescind a published but unimplemented Trump-era regulation that would peg Medicare Part B drug reimbursement for 50 expensive, physician-administered drugs on the lowest price that drug manufacturers get in similar countries. The widely criticized regulation

Read More »

In Fight with National Implications, Calif. 340B Providers Try to Stop Move That Could Result in Millions of Lost Savings

California Gov. Gavin Newsom's twice-delayed executive order that would slash Medicaid reimbursement for 340B-purchased drugs is back on track.

California’s twice-postponed shift of Medicaid (Medi-Cal) managed care prescription drug benefits to Medi-Cal fee for service (FFS) is back on for Jan. 1, 2022, one year later than originally planned.

A similar high-stakes battle over Medicaid reimbursement for 340B-purchased drugs

Read More »

Contrary to Reports, Judge in AstraZeneca Lawsuit Did Not Strike Down 340B Unlimited Contract Pharmacy, Court Clerk Says

U.S. Chief District Judge Leonard Stark did not rule that AstraZeneca is not required to deliver 340B discounts drugs to an unlimited number of contract pharmacies, the court clerk's office said today.

The clerk of the federal district court in Wilmington, Del., confirmed this morning that a judge did not rule that drug manufacturer AstraZeneca is not required to deliver 340B discounts drugs to an unlimited number of contract pharmacies. There were

Read More »

Insulin Manufacturers Colluded on 340B Contract Pharmacy After Joint Lobbying Push Failed, Lawsuit Alleges

Four insulin manufacturers conspired to deny 340B discounts on their products shipped to contract pharmacies after an effort to lobby the Trump administration failed, a lawsuit alleges.

CORRECTION Thursday, Aug. 5, 2021, 8:15 p.m.—Earlier today, we misdescribed Novo Nordisk’s 340B contract pharmacy policy. Beginning on Jan. 1, 2021, Novo Nordisk stopped facilitating bill to/ship to distribution of 340B product to hospital contract pharmacies. We incorrectly said Novo

Read More »

Biopharma Company Apellis Posts 340B Limited Distribution Notice

Apellis has posted a notice on HRSA's website informing 340B entities how they can get 340B pricing on the company's new product, Empaveli, which has a REMS.

Biopharmaceutical company Apellis has announced a limited distribution plan for Empaveli (pegcetacoplan), a newly approved treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic, life-threatening blood disorder.

The U.S. Food and Drug Administration (FDA) approved Empaveli on

Read More »

Health Center Files 340B Contract Pharmacy Antitrust Suit Against Insulin Makers, Seeks Nationwide Class Action Certification

The reception area in Mosaic Health's Illion, N.Y., location. Mosaic accuses four insulin manufacturers in a new lawsuit of conspiring to raise prices for 340B entities that use contract pharmacies.

An upstate New York health center has sued the nation’s four major insulin manufacturers for allegedly conspiring to stop offering 340B pricing when covered entities use contract pharmacies.

Mosaic Health’s July 30 lawsuit claims that insulin manufacturers’ Sanofi, Eli

Read More »

Boehringer Ingelheim Halts 340B Pricing on Contract Pharmacy Drugs

Boehringer Ingelheim on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals use contract pharmacies.

Boehringer Ingelheim (BI) on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals contract with pharmacies to dispense the medicines, hospitals reported yesterday.

BI this morning confirmed that it has begun denying 340B pricing

Read More »

Infrastructure Bill Excludes Spread-Pricing Language That 340B Entities Oppose

An infrastructure-spending bill nearing a vote in the U.S. Senate excludes Medicaid managed care “spread pricing” language that 340B entities have been fending off since 2019.

340B covered entities dodged a bullet Sunday when U.S. Senate negotiators released the text of a $550 billion bipartisan infrastructure-spending bill. It did not contain Medicaid managed care “spread pricing” language that entities have been fending off since 2019. Entities

Read More »

Feds and Lilly Make Their Case to Federal Judge in Key Hearing Today

U.S.District Judge Sarah Evans Barker held a hearing today in drug manufacturer Eli Lilly's 340B contract pharmacy lawsuit against HRSA.

Attorneys for the government and drug manufacturer Eli Lilly dueled over the legality of 340B contract pharmacy requirements during a hearing before a federal district judge in Indianapolis today.

Stakeholders are watching the Lilly case closely because, given how far

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live